On March 6, 2024, Sionna Therapeutics, Inc. closed the transaction. The company has amended the terms of the transaction. The company has received $182,000,000 in the transaction.

The transaction was led by new investor, Enavate Sciences, and included participation from new investors, Perceptive Advisors LLC, Viking Global Investors LP, returning investors, RA Capital Management, L.P., OrbiMed Advisors LLC, Atlas Venture L.P., Cystic Fibrosis Foundation,TPG The Rise Fund, a fund managed by TPG Capital, L.P., funds and accounts advised by T. Rowe Price Group, Inc., Q Healthcare Holding LLC. This funding round was over-subscribed and upsized. As part of the transaction, Edd Fleming of Enavate Sciences will join board of directors of the company.

The company raised $332,000,000 in funding till date.